Detralex
PreclinicalSmall molecule
Detralex is one of 32 small molecule programs targeting Hemorrhoid. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Botox
RRevance Therapeutics, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Marcaine
IInnocoll
Approved
Celestone
SSchering-Plough
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Kenalog
BBassett Healthcare
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemorrhoid1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Detralex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SServier Russia